Evidence map›Paper›PMID 35204404›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Deep Learning Prediction of Response to Anti-VEGF among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS).

Saif Aldeen Alryalat, Mohammad Al-Antary, Yasmine Arafa, Babak Azad, Cornelia Boldyreff, Tasneem Ghnaimat, Nada Al-Antary, Safa Alfegi, Mutasem Elfalah, Mohammed Abu-Ameerh

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Deep learning in optical coherence tomography: Where are the gaps?Clinical & experimental ophthalmology · 2023
    Review
  16. Artificial Intelligence and Glaucoma: Going Back to Basics.Clinical ophthalmology (Auckland, N.Z.) · 2023
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saif Aldeen AlryalatDepartment of Ophthalmology, The University of Jordan Hospital, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0001-5588-9458
Mohammad Al-AntarySchool of Computing and Mathematical Sciences, University of Greenwich, London SE10 9LS, UK.ORCID 0000-0001-8820-2843
Yasmine ArafaSchool of Computing and Mathematical Sciences, University of Greenwich, London SE10 9LS, UK.
Babak AzadSchool of Computer Engineering, Iran University of Science and Technology, Tehran 13114-16846, Iran.ORCID 0000-0002-0571-1173
Cornelia BoldyreffSchool of Computing and Mathematical Sciences, University of Greenwich, London SE10 9LS, UK.
Tasneem GhnaimatDepartment of Computer Science, Princess Sumaya University for Technology, Amman 11941, Jordan.
Nada Al-AntaryIbn Al Haytham Hospital, Amman 11190, Jordan.ORCID 0000-0003-3336-8242
Safa AlfegiTripoli Central Hospital, Tripoli 22131, Libya.ORCID 0000-0001-7303-4066
Mutasem ElfalahDepartment of Ophthalmology, The University of Jordan Hospital, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0002-9677-6203
Mohammed Abu-AmeerhDepartment of Ophthalmology, The University of Jordan Hospital, The University of Jordan, Amman 11942, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic macular edema (DME) is the most common cause of visual impairment among patients with diabetes mellitus. Anti-vascular endothelial growth factors (Anti-VEGFs) are considered the first line in its management. The aim of this research has been to develop a deep learning (DL) model for predicting response to intravitreal anti-VEGF injections among DME patients. The research included treatment naive DME patients who were treated with anti-VEGF. Patient's pre-treatment and post-treatment clinical and macular optical coherence tomography (OCT) were assessed by retina specialists, who annotated pre-treatment images for five prognostic features. Patients were also classified based on their response to treatment in their post-treatment OCT into either good responder, defined as a reduction of thickness by >25% or 50 µm by 3 months, or poor responder. A novel modified U-net DL model for image segmentation, and another DL EfficientNet-B3 model for response classification were developed and implemented for predicting response to anti-VEGF injections among patients with DME. Finally, the classification DL model was compared with different levels of ophthalmology residents and specialists regarding response classification accuracy. The segmentation deep learning model resulted in segmentation accuracy of 95.9%, with a specificity of 98.9%, and a sensitivity of 87.9%. The classification accuracy of classifying patients' images into good and poor responders reached 75%. Upon comparing the model's performance with practicing ophthalmology residents, ophthalmologists and retina specialists, the model's accuracy is comparable to ophthalmologist's accuracy. The developed DL models can segment and predict response to anti-VEGF treatment among DME patients with comparable accuracy to general ophthalmologists. Further training on a larger dataset is nonetheless needed to yield more accurate response predictions.

Indexed as

anti-VEGFartificial intelligencedeep learningdiabetic retinopathymacular edema

Identifiers

PMID35204404
PMCPMC8870773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.